Briefly, effector cells were incubated with P815 cells pre-coated for 30 min with the mAb of interest (irrelevant mouse IgG1: 11 μg/mL, anti-NKp46 (clone BAB281, Beckman Coulter): 1 μg/mL, anti-DNAM (clone DX11, BD Biosciences): 5 μg/mL, anti-NKG2A (clone 131411, R&D Systems): 5 μg/mL, anti-CD277 20.1: 10 μg/mL) according to a 1:1 effector:target (E/T) ratio. Similar stimulation conditions have been used with the CD16 mAb (clone 3G8, BD Biosciences). Cytotoxic tests were performed in 4-h assays in the presence of GolgiStop® and soluble FITC-labeled CD107a/b mAbs (both from BD Biosciences), then the cells were stained for surface markers (PeCy7-CD56 (Beckman Coulter, Immunotech), fixed and permeabilized
(Cytofix/Cytoperm®) then stained with anti-IFN-γ PLX4032 mouse mAb (Beckman Coulter, Immunotech). Cells were finally re-suspended in PBS 2% paraformaldehyde and extemporaneously analyzed on a BD FACS Canto® (BD Biosciences). The degree of activation of NK cells was measured based on the percentage of cells positive for CD107a/b (degranulation) and/or the production of inflammatory cytokine (IFN-γ). To determine the production of cytokines, cell-free supernatants selleck compound were collected at 48 h and assayed for IL-2 and IFN-γ by ELISA using
OptEIA kits (BD Pharmingen) according to manufacturer’s instructions. After 8 h of transfection, KGHYG-1 cells were incubated with plate-bound mAbs in a 96-well plate. For NKp30 and/or CD277 isoform stimulation, anti-FLAG mAb was preadsorbed at 4μg/100 μL/well and anti-NKp30 mAb at 1 μg/100 μL/well.
Upon 4h of stimulation, intracellular IFN-γ stainings are performed with a PE-labelled specific Ab (Beckman Coulter). The construct p3XFlagBTN3A1 (BTN3A1) corresponding to the WT full-length human BTN3A1 cDNA deleted from its signal peptide sequence and tagged with 3× Flag epitope in the 5′ end was generated by subcloning of pCR-BluntII-TOPO vector containing BTN3A1 (cDNA clone IRCMp5012H1242D, Source BioScience LifeSciences, Nottingham, UK) into the p3×FLAG-myc-CMV-25™ vector (SIGMA Life Science), using the restriction sites EcoRI/XbaI. The construct p3×FlagBTN3A2 (BTN3A2) corresponding to the WT full-length Pregnenolone human BTN3A2 cDNA deleted from its signal peptide sequence and tagged with 3× FLAG epitope in the 5′ end, was generated by subcloning of pOBT7 vector containing BTN3A2 (cDNA clone IRAUp969E0222D, Source BioScience LifeSciences, Nottingham, UK) into the p3×FLAG-myc-CMV-25™ vector, using the restriction sites EcoRI/XbaI. The construct p3×FlagBTN3A3 (BTN3A3) corresponding to the WT full-length human BTN3A3 cDNA deleted from its signal peptide sequence and tagged with 3× FLAG epitope in the 5′ end was generated by subcloning of pOTB7 vector containing BTN3A1 (cDNA clone IRAUp969E1250D, Source BioScience LifeSciences, Nottingham, UK) into the p3×FLAG-myc-CMV-25™ vector, using the restriction sites EcoRI/XbaI.